These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 6706581

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Intrafocal BCG therapy of metastasizing malignant melanoma].
    Kunze J, Lesch R, Plagwitz R, Hagedorn M.
    Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
    [Abstract] [Full Text] [Related]

  • 3. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Nov; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 4. [Multiple BCG-induced ulcers after subcutaneous vaccination in the framework of immunochemotherapy in malignant melanoma].
    Korting HC, Strasser S, Konz B.
    Hautarzt; 1988 Mar; 39(3):170-3. PubMed ID: 3378889
    [Abstract] [Full Text] [Related]

  • 5. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1979 Mar; 49(2):140-5. PubMed ID: 475550
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma.
    Briggs PC, Heckler FR.
    Plast Reconstr Surg; 1988 Jun; 81(6):952-3. PubMed ID: 3375359
    [Abstract] [Full Text] [Related]

  • 9. Intralesional BCG application in malignant melanoma.
    Sopková B, Kolár V.
    Neoplasma; 1976 Jun; 23(4):421-6. PubMed ID: 794745
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Results in the use of immunochemotherapy in patients with cutaneous malignant melanoma].
    Calbo L, Gorgone S, Palmeri R, Salibra M, Melita P.
    Chir Ital; 1983 Aug; 35(4):519-25. PubMed ID: 6680859
    [Abstract] [Full Text] [Related]

  • 12. Adjuvant combination immunotherapy (BCG and levamisole) in malignant melanoma.
    Dandapat MC, Mohapatra SK, Patra SK.
    Indian J Cancer; 1985 Jun; 22(2):100-7. PubMed ID: 3842124
    [No Abstract] [Full Text] [Related]

  • 13. Primary inoculation tuberculosis after immunotherapy for malignant melanoma with BCG vaccine.
    Caplan SE, Kauffman CL.
    J Am Acad Dermatol; 1996 Nov; 35(5 Pt 1):783-5. PubMed ID: 8912582
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P.
    Dermatology; 1996 Nov; 193(2):105-9. PubMed ID: 8884144
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE.
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [Abstract] [Full Text] [Related]

  • 19. Treatment of malignant melanoma by intratumoral injection of BCG.
    Pinsky CM, Hirshaut Y, Oettgen HF.
    Natl Cancer Inst Monogr; 1973 Dec; 39():225-8. PubMed ID: 4595322
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.